Cellular reprogramming to reverse disease and aging
Biotech📍 San Francisco, CAFounded 2021
Current Valuation
Private
PRIVATE
Altos Labs is a longevity biotech pursuing cellular rejuvenation programming to restore cell health and resilience. It launched in 2021 with roughly $3B in funding and an all-star scientific roster.
Company Profile
CEO
Hal Barron
Founded
2021
HQ
San Francisco, CA
Total Raised
$3.0B
IPO Status
private
Fundraising Status
privateTotal raised $3.0B
Secondary Market
Implied price / share
$15.57
Open interest
6
Secondary price return by period
Implied per-share price from private secondary transactions, as of Jun 2026. This is a point estimate, not a quote — the feed carries no bid, ask or spread, and a secondary print is evidence of what someone paid on that date rather than a live market. Compare across every tracked name →
Products
Cellular reprogramming / rejuvenation research
Competitors
Retro Biosciences · NewLimit · Calico
BiotechLongevityCellular ReprogrammingDeep Tech
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of recent date. Refreshed quarterly.